Aptus Capital Advisors LLC Buys 98,825 Shares of Danaher Corporation $DHR

Aptus Capital Advisors LLC grew its holdings in Danaher Corporation (NYSE:DHR) by 1,396.2% in the first quarter, HoldingsChannel reports. The institutional investor owned 105,903 shares of the conglomerate’s stock after acquiring an additional 98,825 shares during the period. Aptus Capital Advisors LLC’s holdings in Danaher were worth $21,710,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in DHR. GHP Investment Advisors Inc. raised its stake in shares of Danaher by 396.0% in the 1st quarter. GHP Investment Advisors Inc. now owns 124 shares of the conglomerate’s stock valued at $25,000 after buying an additional 99 shares in the last quarter. Heck Capital Advisors LLC acquired a new stake in shares of Danaher during the 4th quarter worth about $27,000. Sierra Ocean LLC increased its position in Danaher by 116.9% in the 1st quarter. Sierra Ocean LLC now owns 141 shares of the conglomerate’s stock valued at $29,000 after acquiring an additional 76 shares in the last quarter. Smallwood Wealth Investment Management LLC bought a new position in Danaher in the 1st quarter worth approximately $31,000. Finally, Dunhill Financial LLC lifted its holdings in Danaher by 68.4% during the 1st quarter. Dunhill Financial LLC now owns 165 shares of the conglomerate’s stock worth $34,000 after buying an additional 67 shares in the last quarter. Institutional investors and hedge funds own 79.05% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have recently commented on the stock. Robert W. Baird lifted their price target on shares of Danaher from $225.00 to $226.00 and gave the stock an “outperform” rating in a research report on Friday, July 18th. JPMorgan Chase & Co. cut their price target on shares of Danaher from $280.00 to $260.00 and set an “overweight” rating on the stock in a research note on Tuesday, April 22nd. Leerink Partners boosted their price objective on shares of Danaher from $225.00 to $230.00 and gave the stock an “outperform” rating in a research report on Wednesday, April 23rd. Scotiabank upgraded shares of Danaher from a “sector perform” rating to a “sector outperform” rating and set a $275.00 target price on the stock in a report on Friday, July 11th. Finally, Wall Street Zen upgraded shares of Danaher from a “hold” rating to a “buy” rating in a report on Friday, June 27th. Three investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the company’s stock. Based on data from MarketBeat.com, Danaher currently has a consensus rating of “Moderate Buy” and an average price target of $247.61.

Danaher Stock Up 0.3%

NYSE:DHR opened at $210.84 on Monday. The company has a market cap of $150.97 billion, a PE ratio of 44.86, a P/E/G ratio of 2.94 and a beta of 0.73. The firm’s 50 day simple moving average is $199.94 and its 200 day simple moving average is $199.54. The company has a debt-to-equity ratio of 0.32, a current ratio of 1.62 and a quick ratio of 1.22. Danaher Corporation has a one year low of $171.00 and a one year high of $279.90.

Danaher (NYSE:DHR) last announced its earnings results on Tuesday, July 22nd. The conglomerate reported $1.80 earnings per share for the quarter, topping analysts’ consensus estimates of $1.64 by $0.16. The business had revenue of $5.94 billion during the quarter, compared to the consensus estimate of $5.83 billion. Danaher had a net margin of 14.21% and a return on equity of 10.70%. Danaher’s quarterly revenue was up 3.4% on a year-over-year basis. During the same quarter last year, the firm earned $1.72 earnings per share. On average, research analysts anticipate that Danaher Corporation will post 7.63 earnings per share for the current year.

Danaher Company Profile

Danaher Corporation designs, manufactures, and markets professional, medical, industrial, and commercial products and services worldwide. The Biotechnology segments offers bioprocess technologies, consumables, and services that advance, accelerate, and integrate the development and manufacture of therapeutics; cell line and cell culture media development services; cell culture media, process liquids and buffers for manufacturing, chromatography resins, filtration technologies, aseptic fill finish; single-use hardware and consumables and services, such as the design and installation of full manufacturing suites; lab filtration, separation, and purification; lab-scale protein purification and analytical tools; reagents, membranes, and services; and healthcare filtration solutions.